Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HER-2 G778_P780dup
i
Other names:
ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
HER-2 amplification + RAS wild-type + BRAF wild-type (9)
HER-2 positive + HER-2 amplification (4)
RAS wild-type + HER-2 positive (4)
HER-2 amplification + KRAS G12D (3)
BRAF wild-type + HER-2 positive (2)
BRCA1 mutation + HER-2 negative (2)
BRCA2 mutation + HER-2 negative (2)
HER-2 S310F + HER-2 amplification (2)
HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)
HER-2 amplification + HER-2 L755S (2)
HER-2 amplification + PD-L1 expression (2)
HER-2 amplification + RAS wild-type (2)
HER-2 expression + HER-2 D769H (2)
HER-2 expression + HER-2 L869R (2)
HER-2 expression + HER-2 amplification (2)
HER-2 expression + TMB-H (2)
RAS wild-type + BRAF wild-type + HER-2 positive (2)
TMB-H + HER-2 positive (2)
AR positive + HER-2 amplification (1)
BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)
EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)
EGFR T790M + HER-2 amplification (1)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)
ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)
ER positive + HER-2 D769H + HER-2 V777L (1)
ERBB2 G778A + CCNE1 amplification (1)
ERBB3 mutation + HER-2 amplification (1)
ERBB4 mutation + HER-2 positive (1)
HER-2 amplification + AXL expression (1)
HER-2 amplification + BRAF wild-type (1)
HER-2 amplification + CCNE1 expression (1)
HER-2 amplification + EGFR mutation (1)
HER-2 amplification + ER positive + PGR negative (1)
HER-2 amplification + HER-2 R157W (1)
HER-2 amplification + HER-2 mutation (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 elevation (1)
HER-2 elevation + TMB-H (1)
HER-2 elevation + TMB-L (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HER-2 mutation + HER-2 positive (1)
HER-2 mutation + TMB-H (1)
HER-2 overexpression + CCNE1 amplification (1)
HER-2 overexpression + HER-2 amplification (1)
HER-2 overexpression + KRAS G12C (1)
HER-2 overexpression + KRAS wild-type (1)
HER-2 overexpression + PTEN deletion (1)
HER-2 overexpression + RAS wild-type (1)
HER-2 positive + APC mutation (1)
HER-2 positive + GATA6 amplification (1)
HER-2 positive + MYC amplification (1)
HER-2 positive + TP53 mutation (1)
HER-2 underexpression + CCNE1 amplification (1)
HR positive + HER-2 amplification (1)
HR positive + HER-2 mutation (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS mutation + HER-2 positive (1)
MSI-H + HER-2 amplification (1)
MSI-H/dMMR + HER-2 mutation (1)
NF1 mutation + HER-2 positive (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PIK3C3 mutation + HER-2 positive (1)
PIK3CA H1047R + HER-2 amplification (1)
PIK3CA mutation + HER-2 amplification (1)
PIK3CA mutation + HER-2 positive (1)
PIK3CA mutation + HR positive + HER-2 negative (1)
PIK3R1 mutation + HER-2 positive (1)
POLE E790Q + ERBB2 amplification + TMB-H (1)
RAS wild-type + HER-2 amplification (1)
RAS wild-type + HER-2 overexpression (1)
STAT6 deletion + HER-2 overexpression (1)
ER negative + HER-2 positive + PIK3CA H1047R (0)
ER positive + HER-2 negative + ER mutation (0)
HER-2 amplification + KRAS G12C (0)
HER-2 exon 20 mutation + HER-2 amplification (0)
HER-2 positive + FGFR1 amplification (0)
HER-2-H (0)
HR positive + HER-2 negative + TMB-L (0)
PIK3CA E453K + HER-2 positive (0)
PIK3CA E542K + HER-2 positive (0)
PIK3CA E542Q + HER-2 positive (0)
PIK3CA H1047L + HER-2 positive (0)
PIK3CA H1047R + HER-2 positive (0)
PIK3CA N345K + HER-2 positive (0)
PIK3CA amplification + HER-2 positive (0)
HER-2 amplification + RAS wild-type + BRAF wild-type (9)
HER-2 positive + HER-2 amplification (4)
RAS wild-type + HER-2 positive (4)
HER-2 amplification + KRAS G12D (3)
BRAF wild-type + HER-2 positive (2)
BRCA1 mutation + HER-2 negative (2)
BRCA2 mutation + HER-2 negative (2)
HER-2 S310F + HER-2 amplification (2)
HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)
HER-2 amplification + HER-2 L755S (2)
HER-2 amplification + PD-L1 expression (2)
HER-2 amplification + RAS wild-type (2)
HER-2 expression + HER-2 D769H (2)
HER-2 expression + HER-2 L869R (2)
HER-2 expression + HER-2 amplification (2)
HER-2 expression + TMB-H (2)
RAS wild-type + BRAF wild-type + HER-2 positive (2)
TMB-H + HER-2 positive (2)
AR positive + HER-2 amplification (1)
BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)
EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)
EGFR T790M + HER-2 amplification (1)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)
ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)
ER positive + HER-2 D769H + HER-2 V777L (1)
ERBB2 G778A + CCNE1 amplification (1)
ERBB3 mutation + HER-2 amplification (1)
ERBB4 mutation + HER-2 positive (1)
HER-2 amplification + AXL expression (1)
HER-2 amplification + BRAF wild-type (1)
HER-2 amplification + CCNE1 expression (1)
HER-2 amplification + EGFR mutation (1)
HER-2 amplification + ER positive + PGR negative (1)
HER-2 amplification + HER-2 R157W (1)
HER-2 amplification + HER-2 mutation (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 elevation (1)
HER-2 elevation + TMB-H (1)
HER-2 elevation + TMB-L (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HER-2 mutation + HER-2 positive (1)
HER-2 mutation + TMB-H (1)
HER-2 overexpression + CCNE1 amplification (1)
HER-2 overexpression + HER-2 amplification (1)
HER-2 overexpression + KRAS G12C (1)
HER-2 overexpression + KRAS wild-type (1)
HER-2 overexpression + PTEN deletion (1)
HER-2 overexpression + RAS wild-type (1)
HER-2 positive + APC mutation (1)
HER-2 positive + GATA6 amplification (1)
HER-2 positive + MYC amplification (1)
HER-2 positive + TP53 mutation (1)
HER-2 underexpression + CCNE1 amplification (1)
HR positive + HER-2 amplification (1)
HR positive + HER-2 mutation (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS mutation + HER-2 positive (1)
MSI-H + HER-2 amplification (1)
MSI-H/dMMR + HER-2 mutation (1)
NF1 mutation + HER-2 positive (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PIK3C3 mutation + HER-2 positive (1)
PIK3CA H1047R + HER-2 amplification (1)
PIK3CA mutation + HER-2 amplification (1)
PIK3CA mutation + HER-2 positive (1)
PIK3CA mutation + HR positive + HER-2 negative (1)
PIK3R1 mutation + HER-2 positive (1)
POLE E790Q + ERBB2 amplification + TMB-H (1)
RAS wild-type + HER-2 amplification (1)
RAS wild-type + HER-2 overexpression (1)
STAT6 deletion + HER-2 overexpression (1)
ER negative + HER-2 positive + PIK3CA H1047R (0)
ER positive + HER-2 negative + ER mutation (0)
HER-2 amplification + KRAS G12C (0)
HER-2 exon 20 mutation + HER-2 amplification (0)
HER-2 positive + FGFR1 amplification (0)
HER-2-H (0)
HR positive + HER-2 negative + TMB-L (0)
PIK3CA E453K + HER-2 positive (0)
PIK3CA E542K + HER-2 positive (0)
PIK3CA E542Q + HER-2 positive (0)
PIK3CA H1047L + HER-2 positive (0)
PIK3CA H1047R + HER-2 positive (0)
PIK3CA N345K + HER-2 positive (0)
PIK3CA amplification + HER-2 positive (0)
›
Associations
(5)
News
Trials
Search handles
@DrJNaidoo
@Latinamd
@LeXiuning
@StephenVLiu
Search handles
@DrJNaidoo
@Latinamd
@LeXiuning
@StephenVLiu
Filter by
Latest
1year
Poziotinib in Treatment-Naïve HER2 Exon 20 lung cancers: ZENITH20-Cohort 4 ORR 39%, DoR 7.6 mon, G778_P780dupGSP ORR 71%. @EGFRResisters @Exon20Group https://t.co/DvfkrlAD23 (@LeXiuning)
1 year ago
EGFR exon 20 • HER2 exon 20
|
HER-2 (Human epidermal growth factor receptor 2)
|
EGFR exon 20 insertion • EGFR exon 20 mutation • HER-2 G778_P780dup • HER-2 exon 23 mutation
|
Pozenveo (poziotinib)
1year
Poziotinib in Treatment-Naïve HER2 Ex 20 Mutations: ZENITH20-4- Ph2 @JTOonline - N=80 - ORR 39%; DCR 73%; mPFS 5.6m - TRAEs: rash 45% stomatitis, diarrhea 15% - ⬆️ORR 71% in G778_P780dupGS ➡️ FDA declined 2nd line approval in 2022 pending more data #lcsm https://t.co/6CuMFdBTPk (@Latinamd)
1 year ago
FDA event
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation • HER-2 G778_P780dup
|
Pozenveo (poziotinib)
1year
ZENITH20 Ph 2 Trial Poziotinib in HER2mt NSCLC @JTOonline: - 80pts - ORR 39%; DCR 73%; mPFS 5.6m - TRAEs: rash, stomatitis, diarrhea - G778_P780dupGSP HER2 mtn had ⬆️ORR 71% Early signal that mtn subtype matters in HER2mt NSCLC w pozi @OncoAlert #LCSM https://t.co/GXaoXlhOsb (@DrJNaidoo)
1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 G778_P780dup
|
Pozenveo (poziotinib)
1year
Phase II study of 1L poziotinib in #HER2 NSCLC @JTOonline. In 80pts (47 at 16mg qd, 33 at 8mg bid), RR 39%, DCR 73%, mDOR 5.7m, mPFS 5.6m. G3+ AEs include rash (45% qd, 39% bid), mucositis (21%, 15%), diarrhea (15%, 21%). RR 71% in G778_P780dupGSP. https://t.co/hM5IF7UwHb (@StephenVLiu)
1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 G778_P780dup
|
Pozenveo (poziotinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login